The Centers for Disease Control and Prevention debuted a new public health awareness campaign this week focused on educating ...

After telegraphing an investigation in November, the FDA has moved to restrict the use of bluebird bio’s gene therapy Skysona ...

The chapter on Pfizer and BioNTech’s mRNA patent feud with Germany’s CureVac is coming to a close, even as lawsuits over the ...

With the FDA approval of its zongertinib in certain non-small cell lung cancer (NSCLC) patients, 175-year-old Boehringer ...

Genmab and AbbVie are taking key steps toward moving their blood cancer drug Epkinly into earlier lines of treatment in ...

Quarterly revenue from Yescarta came in at $393 million, which was a 5% decline from the second quarter of last year, while ...

Following a barrage of letters from President Donald Trump urging 17 large pharmaceutical companies to implement Most Favored ...

Sanofi is pulling its PCSK9 drug Praluent from the Chinese market. President Donald Trump said U.S. pharmaceutical tariffs may eventually reach 250%. | Sanofi is pulling its PCSK9 drug Praluent from ...

Contract Development and Manufacturing Organizations (CDMOs) have carved out a lucrative niche within the biopharma industry, ...

In line with the Trump administration’s goal to curb the U.S.’ reliance on overseas drug manufacturing, the FDA has deployed ...

Otte took on the title in February, the culmination of nearly 25 years spent with the Danish drugmaker. As of his departure ...

Merck pulled off its $10 billion buyout of Verona Pharma last month with little of the wheeling and dealing that typically ...